90Y-ibritumomab tiuxetan (Zevalin) is currently approved for radioimmunotherapy of patients with relapsed or refractory follicular non-Hodgkins lymphoma pretreated with rituximab...
Keywords: Ibritumomab-Tiuxetan, ZevalinŽ, Yttrium-90, Radioimmuntherapie, Aktivimeter, Strahlenschutz
01/2005 | Nuklearmedizin, Schattauer